,REPOSITORY ID,REPOSITORY LINK,SAMPLE NUMBER,STUDY TITLE,STUDY LINK,ASSAY TYPE,TECHNOLOGY,COUNTRY,DISEASE,DOID,STUDY DESIGN,BODY SITE,PLATFORM,PARTICIPANT FEATURES,AVERAGE SPOTLENGTH,RUN ID,Sample ID,Sample Name,COLLECTION DATE,LIBRARY LAYOUT,LAT LON,SAMPLE TYPE,ETHNICITY,ELO,URBANZATION,REGION,CITYVILLAGE,TARGET AMPLICON,DIET
0,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428379,SRS3406667,SAMPLE_1123-9,06/26/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
1,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428380,SRS3406662,SAMPLE_1125-1,09/19/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
2,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428381,SRS3406798,SAMPLE_1456-4,02/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
3,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428382,SRS3406846,SAMPLE_1872-1,02/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
4,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428383,SRS3406887,SAMPLE_0903-9,06/26/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
5,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428393,SRS3406780,SAMPLE_2604-9,01/12/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
6,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428394,SRS3406843,SAMPLE_1742-1,01/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
7,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428403,SRS3406721,SAMPLE_0494-1,06/13/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
8,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428405,SRS3406679,SAMPLE_0333-4,08/13/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
9,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428406,SRS3406748,SAMPLE_0532-4,10/11/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
10,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,247.0,SRR7428409,SRS3406749,SAMPLE_0532-1,07/09/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
11,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428410,SRS3406804,SAMPLE_1981-4,05/16/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
12,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428411,SRS3406767,SAMPLE_1361-9,07/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
13,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428413,SRS3406924,SAMPLE_2251-4,07/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
14,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428415,SRS3406802,SAMPLE_1872-9,08/13/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
15,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428416,SRS3406698,SAMPLE_1143-4,01/30/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
16,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428417,SRS3406703,SAMPLE_1143-1,10/11/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
17,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428419,SRS3406670,SAMPLE_1125-4,01/16/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
18,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428422,SRS3406701,SAMPLE_1192-1,10/03/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
19,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428423,SRS3406702,SAMPLE_1143-9,07/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
20,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428424,SRS3406807,SAMPLE_1974-4,05/16/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
21,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428426,SRS3406769,SAMPLE_1271-4,02/13/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
22,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,246.0,SRR7428428,SRS3406925,SAMPLE_2251-9,12/18/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
23,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428430,SRS3406881,SAMPLE_2595-4,07/25/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
24,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,247.0,SRR7428431,SRS3406750,SAMPLE_0494-4,09/24/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
25,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293301,SRS3406942,SAMPLE_1101-9,06/12/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
26,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293304,SRS3406939,SAMPLE_0982-1,09/10/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
27,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,572.0,SRR7293306,SRS3406936,SAMPLE_0990-1,09/12/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
28,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,556.0,SRR7293307,SRS3406937,SAMPLE_0982-2,10/10/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
29,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293308,SRS3406935,SAMPLE_1101-4,01/09/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
30,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293309,SRS3406933,SAMPLE_1101-1,10/03/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
31,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,598.0,SRR7293310,SRS3406934,SAMPLE_6002,02/09/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
32,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293311,SRS3406932,SAMPLE_6004,02/09/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
33,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293312,SRS3406931,SAMPLE_6000,06/11/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
34,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293313,SRS3406930,SAMPLE_6001,02/09/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
35,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293314,SRS3406929,SAMPLE_2325-2,05/30/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
36,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,573.0,SRR7293315,SRS3406927,SAMPLE_2446-1,03/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
37,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293316,SRS3406928,SAMPLE_6005,02/09/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
38,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293317,SRS3406926,SAMPLE_6006,02/10/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
39,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293318,SRS3406924,SAMPLE_2251-4,07/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
40,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293319,SRS3406925,SAMPLE_2251-9,12/18/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
41,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,581.0,SRR7293320,SRS3406923,SAMPLE_2282-1,03/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
42,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293321,SRS3406922,SAMPLE_2325-1,04/29/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
43,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293322,SRS3406921,SAMPLE_2105-1,02/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
44,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,579.0,SRR7293323,SRS3406920,SAMPLE_2105-2,03/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
45,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,576.0,SRR7293324,SRS3406919,SAMPLE_2105-3,04/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
46,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,547.0,SRR7293328,SRS3406915,SAMPLE_6043,03/04/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
47,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,580.0,SRR7293329,SRS3406914,SAMPLE_6044,03/04/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
48,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,544.0,SRR7293331,SRS3406911,SAMPLE_6035,02/27/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
49,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,582.0,SRR7293332,SRS3406912,SAMPLE_6036,03/03/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
50,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293334,SRS3406910,SAMPLE_8034,04/01/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
51,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,581.0,SRR7293335,SRS3406908,SAMPLE_6045,03/09/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
52,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293337,SRS3406905,SAMPLE_6008,02/10/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
53,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293339,SRS3406904,SAMPLE_0030-1,04/15/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
54,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,575.0,SRR7293340,SRS3406961,SAMPLE_8048,04/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
55,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,579.0,SRR7293342,SRS3406902,SAMPLE_8049,04/25/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
56,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,426.0,SRR7293345,SRS3406899,SAMPLE_8062,05/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
57,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,572.0,SRR7293346,SRS3406898,SAMPLE_8059,05/15/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
58,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293348,SRS3406896,SAMPLE_0903-15,01/13/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
59,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293351,SRS3406893,SAMPLE_0903-4,12/20/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
60,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,539.0,SRR7293352,SRS3406892,SAMPLE_0852-1,08/27/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
61,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293354,SRS3406890,SAMPLE_0903-1,09/10/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
62,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293355,SRS3406889,SAMPLE_0903-12,09/26/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
63,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,531.0,SRR7293356,SRS3406888,SAMPLE_0903-6,03/27/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
64,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293358,SRS3406885,SAMPLE_5042-6,03/19/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
65,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293361,SRS3406882,SAMPLE_5199-1,10/23/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
66,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,536.0,SRR7293362,SRS3406883,SAMPLE_8047,04/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
67,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,573.0,SRR7293365,SRS3406879,SAMPLE_2483-1,04/04/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
68,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293371,SRS3406873,SAMPLE_5263-3,02/19/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
69,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293374,SRS3406870,SAMPLE_8018,03/11/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
70,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293376,SRS3406868,SAMPLE_5042-2,11/07/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
71,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293380,SRS3406865,SAMPLE_5261-1,11/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
72,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293381,SRS3406863,SAMPLE_5042-1,10/09/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
73,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,584.0,SRR7293385,SRS3406858,SAMPLE_0633-9,03/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
74,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293386,SRS3406857,SAMPLE_0633-6,12/05/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
75,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293387,SRS3406856,SAMPLE_0633-4,10/31/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
76,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293389,SRS3406854,SAMPLE_0765-1,07/25/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
77,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,584.0,SRR7293392,SRS3406850,SAMPLE_0827-1,08/27/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
78,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293393,SRS3406851,SAMPLE_0822-1,08/20/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
79,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293394,SRS3406852,SAMPLE_5042-4,01/13/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
80,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,582.0,SRR7293395,SRS3406849,SAMPLE_1872-12,01/13/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
81,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,586.0,SRR7293397,SRS3406847,SAMPLE_1742-4,04/17/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
82,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,553.0,SRR7293398,SRS3406846,SAMPLE_1872-1,02/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
83,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293401,SRS3406843,SAMPLE_1742-1,01/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
84,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293402,SRS3406842,SAMPLE_1742-15,04/02/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
85,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293403,SRS3406841,SAMPLE_5056-3,01/21/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
86,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293405,SRS3406839,SAMPLE_1872-4,05/16/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
87,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293409,SRS3406835,SAMPLE_6013,02/11/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
88,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293412,SRS3406832,SAMPLE_6017,02/13/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
89,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,598.0,SRR7293414,SRS3406830,SAMPLE_6021,02/18/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
90,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293418,SRS3406825,SAMPLE_8025,03/25/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
91,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293419,SRS3406824,SAMPLE_8026,03/25/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
92,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293420,SRS3406822,SAMPLE_1361-4,02/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
93,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293423,SRS3406820,SAMPLE_0633-3,09/26/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
94,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293424,SRS3406819,SAMPLE_0633-1,07/23/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
95,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293427,SRS3406816,SAMPLE_0632-1,07/18/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
96,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293430,SRS3406813,SAMPLE_0588-1,07/11/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
97,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293432,SRS3406811,SAMPLE_5042-3,12/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
98,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293433,SRS3406810,SAMPLE_5297-4,03/12/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
99,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293434,SRS3406809,SAMPLE_5300-1,11/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
100,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293436,SRS3406806,SAMPLE_6057,03/12/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
101,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293438,SRS3406805,SAMPLE_1974-1,02/14/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
102,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293440,SRS3406803,SAMPLE_1981-1,02/14/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
103,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293441,SRS3406802,SAMPLE_1872-9,08/13/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
104,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,588.0,SRR7293443,SRS3406801,SAMPLE_1955-4,04/17/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
105,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,527.0,SRR7293444,SRS3406799,SAMPLE_1902-1,01/17/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
106,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293445,SRS3406798,SAMPLE_1456-4,02/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
107,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293448,SRS3406795,SAMPLE_5056-1,11/07/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
108,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,581.0,SRR7293449,SRS3406794,SAMPLE_5056-2,12/11/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
109,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,584.0,SRR7293450,SRS3406793,SAMPLE_8023,03/19/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
110,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293454,SRS3406789,SAMPLE_0584-1,07/18/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
111,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,598.0,SRR7293455,SRS3406788,SAMPLE_6010,02/11/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
112,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293456,SRS3406787,SAMPLE_0575-1,11/07/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
113,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,575.0,SRR7293458,SRS3406785,SAMPLE_0575-3,09/24/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
114,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,584.0,SRR7293459,SRS3406784,SAMPLE_0575-2,08/20/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
115,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293461,SRS3406783,SAMPLE_0563-18,01/21/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
116,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293462,SRS3406860,SAMPLE_0564-2,07/30/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
117,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293464,SRS3406780,SAMPLE_2604-9,01/12/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
118,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293465,SRS3406779,SAMPLE_5198-1,11/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
119,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293467,SRS3406777,SAMPLE_5098-1,10/23/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
120,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293469,SRS3406775,SAMPLE_5263-2,01/13/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
121,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293474,SRS3406770,SAMPLE_4973-1,10/09/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
122,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293476,SRS3406768,SAMPLE_1361-6,04/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
123,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293477,SRS3406767,SAMPLE_1361-9,07/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
124,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,574.0,SRR7293479,SRS3406765,SAMPLE_1411-1,11/28/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
125,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293482,SRS3406762,SAMPLE_1460-3,01/23/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
126,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293484,SRS3406760,SAMPLE_1539-15,02/26/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
127,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,576.0,SRR7293486,SRS3406759,SAMPLE_8035,04/02/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
128,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293488,SRS3406756,SAMPLE_1271-9,07/17/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
129,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293490,SRS3406754,SAMPLE_1303-3,01/16/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
130,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293493,SRS3406751,SAMPLE_4940-2,11/07/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
131,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,552.0,SRR7293494,SRS3406750,SAMPLE_0494-4,09/24/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
132,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,587.0,SRR7293495,SRS3406749,SAMPLE_0532-1,07/09/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
133,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293496,SRS3406747,SAMPLE_0532-2,08/13/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
134,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,585.0,SRR7293498,SRS3406746,SAMPLE_0532-6,12/12/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
135,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293499,SRS3406828,SAMPLE_0534-1,07/09/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
136,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293500,SRS3406745,SAMPLE_0534-9,03/14/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
137,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,588.0,SRR7293501,SRS3406744,SAMPLE_0537-1,07/09/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
138,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293504,SRS3406739,SAMPLE_1726-1,01/09/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
139,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293506,SRS3406742,SAMPLE_1634-2,01/30/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
140,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,584.0,SRR7293509,SRS3406736,SAMPLE_1625-1,12/12/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
141,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,443.0,SRR7293511,SRS3406734,SAMPLE_1546-1,12/05/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
142,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293513,SRS3406732,SAMPLE_6061,03/12/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
143,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,587.0,SRR7293515,SRS3406730,SAMPLE_8027,03/25/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
144,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293517,SRS3406728,SAMPLE_6054,03/11/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
145,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,584.0,SRR7293519,SRS3406726,SAMPLE_6056,03/11/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
146,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293521,SRS3406724,SAMPLE_6047,03/05/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
147,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,580.0,SRR7293522,SRS3406723,SAMPLE_6052,03/09/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
148,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293524,SRS3406721,SAMPLE_0494-1,06/13/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
149,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293528,SRS3406717,SAMPLE_0456-1,06/28/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
150,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293545,SRS3406700,SAMPLE_1143-3,12/19/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
151,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,567.0,SRR7293550,SRS3406695,SAMPLE_8009,03/19/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
152,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293551,SRS3406694,SAMPLE_8006,03/18/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
153,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293552,SRS3406693,SAMPLE_8007,03/18/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
154,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,588.0,SRR7293558,SRS3406686,SAMPLE_6064,03/18/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
155,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293563,SRS3406681,SAMPLE_0412-1,06/04/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
156,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293564,SRS3406680,SAMPLE_0416-1,06/04/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
157,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293566,SRS3406678,SAMPLE_0333-9,01/23/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
158,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293567,SRS3406677,SAMPLE_5058-1,10/17/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
159,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293568,SRS3406676,SAMPLE_5056-4,02/19/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
160,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293569,SRS3406675,SAMPLE_0422-1,06/04/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
161,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,288.0,SRR7293571,SRS3406673,SAMPLE_8061,05/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
162,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,577.0,SRR7293572,SRS3406672,SAMPLE_1361-2,11/28/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
163,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293575,SRS3406669,SAMPLE_1125-6,03/27/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
164,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,598.0,SRR7293584,SRS3406660,SAMPLE_8016,03/11/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
165,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,575.0,SRR7293586,SRS3406658,SAMPLE_6033,02/26/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
166,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,569.0,SRR7293587,SRS3406657,SAMPLE_6031,02/26/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
167,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293588,SRS3406656,SAMPLE_6026,02/20/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
168,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293589,SRS3406655,SAMPLE_6025,02/19/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
169,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293590,SRS3406690,SAMPLE_6024,02/19/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
170,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,576.0,SRR7293592,SRS3406653,SAMPLE_6030,02/24/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
171,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,577.0,SRR7293593,SRS3406652,SAMPLE_6029,02/24/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
172,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293595,SRS3406650,SAMPLE_6027,02/23/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
173,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,575.0,SRR7293597,SRS3406959,SAMPLE_0044-2,05/23/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
174,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293598,SRS3406944,SAMPLE_8045,04/01/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
175,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,558.0,SRR7293599,SRS3406957,SAMPLE_0162-1,05/08/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
176,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,581.0,SRR7293601,SRS3406955,SAMPLE_0177-1,05/09/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
177,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293603,SRS3406953,SAMPLE_0254-9,01/30/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
178,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293604,SRS3406952,SAMPLE_0254-6,10/31/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
179,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293605,SRS3406949,SAMPLE_0333-1,05/23/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
180,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428384,SRS3406933,SAMPLE_1101-1,10/03/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
181,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428385,SRS3406890,SAMPLE_0903-1,09/10/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
182,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428386,SRS3406893,SAMPLE_0903-4,12/20/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
183,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428387,SRS3406943,SAMPLE_1123-1,10/03/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
184,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428388,SRS3406668,SAMPLE_1123-4,01/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
185,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428389,SRS3406935,SAMPLE_1101-4,01/09/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
186,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428390,SRS3406942,SAMPLE_1101-9,06/12/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
187,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428391,SRS3406735,SAMPLE_1546-4,03/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
188,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428392,SRS3406884,SAMPLE_2604-4,08/07/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
189,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428395,SRS3406734,SAMPLE_1546-1,12/05/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
190,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428396,SRS3406755,SAMPLE_1361-1,10/25/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
191,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428397,SRS3406856,SAMPLE_0633-4,10/31/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
192,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428398,SRS3406822,SAMPLE_1361-4,02/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
193,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428399,SRS3406874,SAMPLE_2604-1,04/23/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
194,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428400,SRS3406839,SAMPLE_1872-4,05/16/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
195,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428401,SRS3406858,SAMPLE_0633-9,03/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
196,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,247.0,SRR7428402,SRS3406678,SAMPLE_0333-9,01/23/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
197,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428404,SRS3406949,SAMPLE_0333-1,05/23/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
198,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,246.0,SRR7428407,SRS3406819,SAMPLE_0633-1,07/23/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
199,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,246.0,SRR7428408,SRS3406764,SAMPLE_1456-1,11/22/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
200,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428412,SRS3406803,SAMPLE_1981-1,02/14/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
201,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428414,SRS3406918,SAMPLE_2251-1,03/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
202,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428418,SRS3406704,SAMPLE_1125-9,07/03/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
203,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428420,SRS3406763,SAMPLE_1271-1,11/08/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
204,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428421,SRS3406773,SAMPLE_1192-4,01/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
205,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428425,SRS3406756,SAMPLE_1271-9,07/17/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
206,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,247.0,SRR7428427,SRS3406880,SAMPLE_2595-1,04/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
207,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428429,SRS3406805,SAMPLE_1974-1,02/14/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
208,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,WGS,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA HISEQ 2500,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,250.0,SRR7428432,SRS3406847,SAMPLE_1742-4,04/17/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,,
209,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293299,SRS3406945,SAMPLE_8043,04/01/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
210,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293300,SRS3406943,SAMPLE_1123-1,10/03/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
211,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293302,SRS3406941,SAMPLE_0943-1,09/12/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
212,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,459.0,SRR7293303,SRS3406940,SAMPLE_0921-1,09/12/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
213,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,525.0,SRR7293305,SRS3406938,SAMPLE_0969-1,09/12/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
214,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293325,SRS3406918,SAMPLE_2251-1,03/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
215,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,585.0,SRR7293326,SRS3406917,SAMPLE_6040,03/03/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
216,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,532.0,SRR7293327,SRS3406916,SAMPLE_6042,03/04/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
217,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,578.0,SRR7293330,SRS3406913,SAMPLE_6034,02/27/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
218,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293333,SRS3406909,SAMPLE_6038,03/03/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
219,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,586.0,SRR7293336,SRS3406906,SAMPLE_6046,03/09/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
220,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,577.0,SRR7293338,SRS3406907,SAMPLE_0028-1,04/17/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
221,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293341,SRS3406903,SAMPLE_8056,05/07/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
222,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,570.0,SRR7293343,SRS3406901,SAMPLE_8053,04/25/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
223,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293344,SRS3406900,SAMPLE_8042,03/26/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
224,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,558.0,SRR7293347,SRS3406897,SAMPLE_8060,05/15/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
225,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293349,SRS3406895,SAMPLE_0903-2,10/11/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
226,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293350,SRS3406894,SAMPLE_0903-3,11/15/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
227,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293353,SRS3406891,SAMPLE_0871-1,08/27/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
228,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293357,SRS3406887,SAMPLE_0903-9,06/26/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
229,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293359,SRS3406886,SAMPLE_2604-6,10/09/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
230,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293360,SRS3406884,SAMPLE_2604-4,08/07/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
231,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,559.0,SRR7293363,SRS3406881,SAMPLE_2595-4,07/25/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
232,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,587.0,SRR7293364,SRS3406880,SAMPLE_2595-1,04/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
233,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293366,SRS3406878,SAMPLE_2471-1,04/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
234,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,581.0,SRR7293367,SRS3406877,SAMPLE_2604-3,07/03/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
235,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293368,SRS3406876,SAMPLE_2604-2,05/29/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
236,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293369,SRS3406875,SAMPLE_2604-12,04/09/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
237,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293370,SRS3406874,SAMPLE_2604-1,04/23/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
238,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293372,SRS3406871,SAMPLE_8020,03/18/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
239,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293373,SRS3406872,SAMPLE_8019,03/18/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
240,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293375,SRS3406869,SAMPLE_8017,03/11/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
241,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293377,SRS3406867,SAMPLE_8014,03/05/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
242,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,579.0,SRR7293378,SRS3406866,SAMPLE_8013,03/05/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
243,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293379,SRS3406864,SAMPLE_8011,03/19/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
244,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,553.0,SRR7293382,SRS3406862,SAMPLE_8022,03/19/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
245,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,588.0,SRR7293383,SRS3406861,SAMPLE_8021,03/19/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
246,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293384,SRS3406859,SAMPLE_0635-1,07/23/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
247,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293388,SRS3406855,SAMPLE_0765-2,08/29/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
248,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,567.0,SRR7293390,SRS3406853,SAMPLE_0691-1,07/25/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
249,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293391,SRS3406960,SAMPLE_0672-1,07/25/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
250,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,578.0,SRR7293396,SRS3406848,SAMPLE_1872-2,03/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
251,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,582.0,SRR7293399,SRS3406845,SAMPLE_1742-2,02/13/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
252,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293400,SRS3406844,SAMPLE_1742-3,03/13/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
253,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293404,SRS3406840,SAMPLE_1872-3,04/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
254,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293406,SRS3406837,SAMPLE_6014,02/12/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
255,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293407,SRS3406838,SAMPLE_6016,02/13/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
256,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293408,SRS3406836,SAMPLE_6012,02/11/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
257,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293410,SRS3406833,SAMPLE_6019,02/17/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
258,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293411,SRS3406834,SAMPLE_6020,02/18/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
259,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,598.0,SRR7293413,SRS3406831,SAMPLE_6018,02/13/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
260,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293415,SRS3406829,SAMPLE_6022,02/18/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
261,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293416,SRS3406827,SAMPLE_4940-4,01/21/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
262,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,559.0,SRR7293417,SRS3406826,SAMPLE_8024,03/25/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
263,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293421,SRS3406823,SAMPLE_8028,03/25/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
264,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293422,SRS3406821,SAMPLE_0633-18,12/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
265,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293425,SRS3406818,SAMPLE_0633-12,06/05/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
266,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293426,SRS3406817,SAMPLE_0622-1,07/18/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
267,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293428,SRS3406815,SAMPLE_0610-1,07/18/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
268,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,556.0,SRR7293429,SRS3406814,SAMPLE_0615-1,07/16/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
269,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293431,SRS3406812,SAMPLE_0599-1,07/16/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
270,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293435,SRS3406808,SAMPLE_6007,02/10/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
271,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293437,SRS3406807,SAMPLE_1974-4,05/16/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
272,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293439,SRS3406804,SAMPLE_1981-4,05/16/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
273,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,588.0,SRR7293442,SRS3406800,SAMPLE_1872-6,05/16/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
274,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,583.0,SRR7293446,SRS3406797,SAMPLE_2033-1,02/14/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
275,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,589.0,SRR7293447,SRS3406796,SAMPLE_2027-1,02/14/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
276,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293451,SRS3406792,SAMPLE_6009,02/11/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
277,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293452,SRS3406791,SAMPLE_4940-3,12/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
278,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,551.0,SRR7293453,SRS3406790,SAMPLE_0584-2,08/15/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
279,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,582.0,SRR7293457,SRS3406786,SAMPLE_0573-1,07/09/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
280,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293460,SRS3406782,SAMPLE_0563-9,03/21/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
281,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,579.0,SRR7293463,SRS3406781,SAMPLE_0564-1,06/27/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
282,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293466,SRS3406778,SAMPLE_5150-1,10/31/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
283,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,584.0,SRR7293468,SRS3406776,SAMPLE_1246-1,10/31/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
284,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293470,SRS3406774,SAMPLE_4940-1,10/03/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
285,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293471,SRS3406772,SAMPLE_5254-1,11/20/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
286,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293472,SRS3406773,SAMPLE_1192-4,01/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
287,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,588.0,SRR7293473,SRS3406771,SAMPLE_5297-1,11/27/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
288,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,588.0,SRR7293475,SRS3406769,SAMPLE_1271-4,02/13/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
289,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293478,SRS3406766,SAMPLE_1398-1,11/22/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
290,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,498.0,SRR7293480,SRS3406764,SAMPLE_1456-1,11/22/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
291,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293481,SRS3406763,SAMPLE_1271-1,11/08/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
292,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293483,SRS3406761,SAMPLE_1539-1,12/05/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
293,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293485,SRS3406758,SAMPLE_1285-1,11/07/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
294,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293487,SRS3406757,SAMPLE_4940-6,03/19/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
295,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293489,SRS3406755,SAMPLE_1361-1,10/25/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
296,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293491,SRS3406753,SAMPLE_0541-1,07/09/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
297,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293492,SRS3406752,SAMPLE_0563-12,06/27/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
298,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293497,SRS3406748,SAMPLE_0532-4,10/11/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
299,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293502,SRS3406743,SAMPLE_1730-1,01/09/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
300,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293503,SRS3406740,SAMPLE_1726-3,04/03/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
301,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293505,SRS3406738,SAMPLE_1634-3,02/27/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
302,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,581.0,SRR7293507,SRS3406741,SAMPLE_1634-1,11/29/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
303,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293508,SRS3406737,SAMPLE_1625-2,01/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
304,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293510,SRS3406735,SAMPLE_1546-4,03/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
305,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293512,SRS3406733,SAMPLE_5297-3,02/12/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
306,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,584.0,SRR7293514,SRS3406731,SAMPLE_6058,03/12/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
307,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,583.0,SRR7293516,SRS3406729,SAMPLE_6055,03/11/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
308,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293518,SRS3406727,SAMPLE_4973-2,11/06/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
309,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,563.0,SRR7293520,SRS3406725,SAMPLE_6048,03/05/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
310,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293523,SRS3406722,SAMPLE_6049,03/05/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
311,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293525,SRS3406720,SAMPLE_0487-1,06/27/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
312,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,588.0,SRR7293526,SRS3406719,SAMPLE_0486-1,06/28/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
313,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,581.0,SRR7293527,SRS3406718,SAMPLE_0457-1,06/28/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
314,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,575.0,SRR7293529,SRS3406715,SAMPLE_0454-1,06/18/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
315,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,585.0,SRR7293530,SRS3406716,SAMPLE_0446-1,06/18/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
316,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293531,SRS3406714,SAMPLE_0426-1,06/11/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
317,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,569.0,SRR7293532,SRS3406713,SAMPLE_4973-3,12/11/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
318,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293533,SRS3406712,SAMPLE_4973-4,01/21/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
319,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293534,SRS3406711,SAMPLE_0494-2,07/16/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
320,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293535,SRS3406710,SAMPLE_0494-12,05/29/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
321,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293536,SRS3406709,SAMPLE_1192-2,11/07/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
322,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,554.0,SRR7293537,SRS3406707,SAMPLE_1192-3,12/13/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
323,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293538,SRS3406708,SAMPLE_8031,03/26/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
324,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293539,SRS3406706,SAMPLE_1143-12,10/09/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
325,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293540,SRS3406705,SAMPLE_1143-2,11/15/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
326,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293541,SRS3406704,SAMPLE_1125-9,07/03/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
327,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,568.0,SRR7293542,SRS3406703,SAMPLE_1143-1,10/11/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
328,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,587.0,SRR7293543,SRS3406702,SAMPLE_1143-9,07/10/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
329,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293544,SRS3406701,SAMPLE_1192-1,10/03/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
330,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,581.0,SRR7293546,SRS3406698,SAMPLE_1143-4,01/30/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
331,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293547,SRS3406699,SAMPLE_8029,03/26/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
332,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,496.0,SRR7293548,SRS3406697,SAMPLE_8055,05/07/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
333,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293549,SRS3406696,SAMPLE_8008,03/18/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
334,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293553,SRS3406692,SAMPLE_8003,03/05/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
335,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,595.0,SRR7293554,SRS3406691,SAMPLE_8004,03/11/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
336,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,580.0,SRR7293555,SRS3406689,SAMPLE_8000,03/05/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
337,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293556,SRS3406688,SAMPLE_8001,03/05/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
338,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,544.0,SRR7293557,SRS3406687,SAMPLE_6062,03/17/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
339,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,561.0,SRR7293559,SRS3406685,SAMPLE_0333-2,06/27/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
340,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,579.0,SRR7293560,SRS3406684,SAMPLE_0333-3,07/30/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
341,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293561,SRS3406683,SAMPLE_0333-12,04/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
342,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293562,SRS3406682,SAMPLE_0333-18,10/23/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
343,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,593.0,SRR7293565,SRS3406679,SAMPLE_0333-4,08/13/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
344,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293570,SRS3406674,SAMPLE_0425-1,06/11/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
345,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293573,SRS3406671,SAMPLE_1361-15,02/05/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
346,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,571.0,SRR7293574,SRS3406670,SAMPLE_1125-4,01/16/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
347,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293576,SRS3406668,SAMPLE_1123-4,01/24/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
348,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293577,SRS3406667,SAMPLE_1123-9,06/26/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
349,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,597.0,SRR7293578,SRS3406666,SAMPLE_1123-2,11/07/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
350,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,546.0,SRR7293579,SRS3406665,SAMPLE_1123-3,12/13/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
351,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,590.0,SRR7293580,SRS3406664,SAMPLE_1125-15,01/13/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
352,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293581,SRS3406663,SAMPLE_1125-2,10/25/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
353,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293582,SRS3406662,SAMPLE_1125-1,09/19/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
354,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293583,SRS3406661,SAMPLE_1125-12,10/09/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
355,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,542.0,SRR7293585,SRS3406659,SAMPLE_8032,04/01/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
356,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,598.0,SRR7293591,SRS3406654,SAMPLE_6023,02/18/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
357,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,579.0,SRR7293594,SRS3406651,SAMPLE_6028,02/26/2015,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
358,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,518.0,SRR7293596,SRS3406958,SAMPLE_0044-3,06/27/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
359,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293600,SRS3406956,SAMPLE_0046-1,04/18/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
360,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,596.0,SRR7293602,SRS3406954,SAMPLE_0167-1,05/08/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
361,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,565.0,SRR7293606,SRS3406951,SAMPLE_0318-1,05/23/2013,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
362,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,592.0,SRR7293607,SRS3406950,SAMPLE_8039,03/25/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
363,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,521.0,SRR7293608,SRS3406948,SAMPLE_8036,04/04/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
364,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,594.0,SRR7293609,SRS3406947,SAMPLE_8033,04/01/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
365,PRJNA450025,PRJNA450025,366.0,EVOLUTION OF THE GUT MICROBIOME FOLLOWING ACUTE HIV-1 INFECTION,31078141.0,AMPLICON,ILLUMINA,MOZAMBIQUE,HIV,526.0,CASE-CONTROL,GUT,ILLUMINA MISEQ,PARTICIPANTS AGED  BETWEEN 20 AND 46 YEARS OLD ANF SOMETIMES TREATED WITH STANDARD ANTIRETROVIRAL THERAPY,591.0,SRR7293610,SRS3406946,SAMPLE_8041,03/26/2014,PAIRED,"-25.969248, 32.573174",STOOL,,,,MANHIÇA,MAPUTO,v3-v4,
